Navigation Links
BioMotiv Names New Chief Executive Officer
Date:8/21/2012

CLEVELAND, Aug. 21, 2012 /PRNewswire/ -- BioMotiv, LLC, today announced the appointment of Baiju R. Shah as its new chief executive officer, and as a member of its Board of Managers, effective September 1, 2012.  Currently, Mr. Shah is president and chief executive officer of BioEnterprise, a business acceleration initiative and partnership among leading Cleveland-area hospitals and health systems.

"We are excited that Baiju Shah will be leading BioMotiv, a key part of the Harrington Project for Discovery and Development," said Achilles A. Demetriou, MD, PhD, BioMotiv board chairman and chief operating officer of University Hospitals (UH).  "With his knowledge of the life science industry, healthcare, business development and the importance of medical innovation, he is the perfect person to lead and grow this unique organization."

BioMotiv has designed a next generation business model that facilitates efficient and profitable development of multiple, early-stage drug candidate programs with the objective of out-licensing significantly enhanced assets to biopharmaceutical companies or venture firms.

"A new business model is just what the biotech industry needs," said Mr. Shah. "In my new role at BioMotiv, we will be developing just such a model, one closely aligned with physician-scientists who are eager to participate in the discovery and development process to bring novel therapies to patient care."

BioMotiv is a part of The Harrington Project for Discovery and Development, a first-of-its-kind $250 million initiative announced by UH in February.  BioMotiv is continuing its plans to raise $100 million in total initial capital as it builds a portfolio of breakthrough discoveries in-licensed from academic medical centers, research institutions, and other sources.

Prior to his decade of work with BioEnterprise, Mr. Shah, a Cleveland native, played a leading role in the Growth and Business Building practice at McKinsey & Company. In the community, he is chair of Global Cleveland and also serves on the boards of Great Lakes Science Center, Saint Luke's Foundation and United Way of Greater Cleveland. Mr. Shah received his J.D. from Harvard Law School and his B.A. from Yale.

"Baiju is a seasoned executive who is highly regarded for his broad range of expertise, and he will be a tremendous asset to this growing company. As we begin to raise capital and develop as a company, we are excited for Baiju to bring his extensive experience supporting the growth of bioscience companies to the leadership at BioMotiv," added Demetriou.   

About The Harrington Project for Discovery and Development

The Harrington Project for Discovery and Development (The Harrington Project), announced in late February, is a first-of-its-kind initiative and is powered by a $50 million gift – the largest donation in UH history – from the Harrington family, recognized entrepreneurs and philanthropists in Cleveland. It includes the UH Harrington Discovery Institute and BioMotiv. Aligning the entities for the first time with an academic medical center as an engine for innovations, The Harrington Project provides a comprehensive model to advance discoveries into development and to create novel therapies for patient care.

For more information about The Harrington Project and the UH Harrington Discovery Institute, go to: UHHarringtonDiscoveryInstitute.org.

For more information about BioMotiv, go to: www.BioMotiv.com.


'/>"/>
SOURCE BioMotiv
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
3. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
4. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
5. Bausch + Lomb Names John Barr Global President Surgical
6. Forbes Names Pharmalot, a UBM Canon Pharmaceutical Media Group Brand, as a Top Social Media Influencer
7. Wake Forest Baptist Names President of Piedmont Triad Research Park and Chief Innovation Officer
8. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
9. Medical Oncology Association of Southern California Purchasing Network (MPN) Names Cardinal Health Specialty Solutions as its Primary Healthcare Solutions Partner
10. MedVantx Names New VP Employer Solutions and Workplace Health
11. Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
Breaking Medicine News(10 mins):